Rett syndrome (RTT) is a neurodevelopmental disorder characterized by developmental regression beginning 6-18 months after birth, followed by a lifetime of intellectual disability, stereotyped behaviors, and motor deficits. RTT is caused by mutations in the gene encoding MeCP2, a methyl-CpG binding protein believed to modulate gene transcription. Gene expression studies of individual brain regions have reported that Mecp2 loss-of-function leads to both activation and repression of its gene targets in mice. Conditional deletion of MeCP2 from different brain regions has revealed unique insights into the role of these structures in mediating particular RTT-like phenotypes. However, the function of MeCP2 in the striatum, a major brain region involved in motor control and executive cognitive functions, has yet to be studied. Here, we characterized the gene expression changes in the striatum of Mecp2 mutant mice. We found a number of differentially expressed genes in the striatum of both constitutive Mecp2-null mice and mice lacking MeCP2 only from forebrain GABAergic neurons. These changes only occurred when MeCP2 expression levels had reached mature levels and RTT-like symptoms were manifest, supporting a role for MeCP2 in maintaining proper brain function. Many of the gene expression changes identified in the striatum have not previously been shown to change in the hypothalamus or cerebellum. Bioinformatic analysis of differentially expressed genes in striatum as well as hypothalamus and cerebellum revealed that loss of MeCP2 does not affect the global landscape of gene expression. Additionally, we uncovered a number of differentially expressed genes in the liver of Mecp2-null mice suggesting an important role for MeCP2 in non-neuronal tissues. Collectively, our data suggest that the differential expression of genes following loss of MeCP2 occurs in a tissue-or cell-type specific manner and thus MeCP2 function should be understood in a cellular context.
Introduction
RTT is a severe X-linked neurological disorder that affects 1 in 10,000-15,000 females. Patients with RTT experience a relatively normal first 6-18 months of life after which they enter a period of developmental stagnation or regression. Subsequently, patients lose learned motor and communication skills, and develop hand stereotypies and gait apraxia (Katz et al., 2012; Neul et al., 2010) . Approximately 95% of RTT cases are associated with mutations in the gene encoding methylCpG binding protein 2 (MeCP2).
Genetic studies using Mecp2 knockout mice, or mice carrying RTT-associated mutations, have established a causal role of MeCP2 in the etiology of RTT (Chen et al., 2001; Goffin et al., 2012; Guy et al., 2001; M. Shahbazian et al., 2002; Pelka, 2006) . Conditional deletion of Mecp2 from the mouse brain recapitulates the phenotypes observed in Mecp2-null mice such as reduced brain and body weight, decreased locomotor activity, motor incoordination, gait and breathing abnormalities (Chen et al., 2001; Guy et al., 2001 ). These studies demonstrate that RTT is primarily a neurological disorder and that MeCP2 is indispensable for proper brain function. Furthermore, conditional deletion of Mecp2 from specific brain regions or specific population of brain cells have demonstrated that different symptoms of RTT may manifest through loss of MeCP2 function from particular brain regions or cell types (Adachi et al., 2009; Chao et al., 2010; Fyffe et al., 2008; Lioy et al., 2011; Samaco et al., 2009; Ward et al., 2011) . However, while specific neurotransmitter systems and neuronal populations play important roles in the etiology of individual RTT-like phenotypes, the large-scale disruption of MeCP2 function is required for the appearance of phenotypes that mimic constitutive Mecp2-null mice (see Goffin and Zhou, 2012 for review).
MeCP2 is a highly abundant nuclear protein that binds methylated CpGs (5mC) in vitro and in vivo (Skene et al., 2010) . Through its interaction with co-repressor complexes, such as Sin3A and histone deacetylases 2 (HDAC2), MeCP2 was originally postulated to repress gene transcription (Nan et al., 1997); however initial gene expression studies did not find significant changes in gene expression upon loss of MeCP2 (Kriaucionis et al., 2006; Tudor et al., 2002) . To reduce the potentially
